{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T22:20:57Z","timestamp":1767997257870,"version":"3.49.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T00:00:00Z","timestamp":1700006400000},"content-version":"vor","delay-in-days":318,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.vaccine.2022.11.048","type":"journal-article","created":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T15:31:34Z","timestamp":1673019094000},"page":"1153-1160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["A phase 3, randomized, controlled, open-label study to evaluate the persistence up to 5\u00a0years of 1 or 2 doses of meningococcal conjugate vaccine MenACWY-TT given with or without 13-valent pneumococcal conjugate vaccine in 12\u201314-month-old children"],"prefix":"10.1016","volume":"41","author":[{"given":"Clare L.","family":"Cutland","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"Peyrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Webber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Newton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Cutler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Perez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.11.048_b0005","first-page":"1","article-title":"Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"62","author":"Cohn","year":"2013","journal-title":"MMWR Recomm Rep"},{"key":"10.1016\/j.vaccine.2022.11.048_b0010","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3389\/fped.2018.00321","article-title":"Invasive Meningococcal Disease in the Vaccine Era","volume":"6","author":"Nadel","year":"2018","journal-title":"Front Pediatr"},{"key":"10.1016\/j.vaccine.2022.11.048_b0015","unstructured":"European Centre for Disease Prevention and Control. Surveillance atlas of infectious diseases, https:\/\/ecdc.europa.eu\/en\/surveillance-atlas-infectious-diseases; 2018 [accessed October 27, 2022]."},{"key":"10.1016\/j.vaccine.2022.11.048_b0020","unstructured":"US Centers for Disease Control and Prevention C. Enhanced Meningococcal Disease Surveillance Report, CDC, https:\/\/www.cdc.gov\/meningococcal\/downloads\/NCIRD-EMS-Report-2019.pdf; 2019 [accessed October 27, 2022]."},{"issue":"3","key":"10.1016\/j.vaccine.2022.11.048_b0025","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1093\/cid\/ciy914","article-title":"Declining Incidence of Invasive Meningococcal Disease in South Africa: 2003\u20132016","volume":"69","author":"Meiring","year":"2019","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2022.11.048_b0030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/1476-072X-6-29","article-title":"Comparative study of meningitis dynamics across nine African countries: a global perspective","volume":"6","author":"Broutin","year":"2007","journal-title":"Int J Health Geogr"},{"issue":"1","key":"10.1016\/j.vaccine.2022.11.048_b0035","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-021-06724-1","article-title":"An overview of bacterial meningitis epidemics in Africa from 1928 to 2018 with a focus on epidemics \u201coutside-the-belt\u201d","volume":"21","author":"Mazamay","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2022.11.048_b0040","first-page":"E121","article-title":"Meningococcal disease in childhood: epidemiology, clinical features and prevention","volume":"56","author":"Bosis","year":"2015","journal-title":"J Prev Med Hyg"},{"key":"10.1016\/j.vaccine.2022.11.048_b0045","doi-asserted-by":"crossref","first-page":"103571","DOI":"10.1016\/j.micpath.2019.103571","article-title":"Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: A systematic review and meta-analysis","volume":"134","author":"Purmohamad","year":"2019","journal-title":"Microb Pathog"},{"key":"10.1016\/j.vaccine.2022.11.048_b0050","unstructured":"MenQuadfi (Meningococcal (Groups A, C, Y, W) Conjugate Vaccine). Full Prescribing Information, Sanofi Pasteur Inc, Swiftwater, PA, 2021."},{"key":"10.1016\/j.vaccine.2022.11.048_b0055","unstructured":"Nimenrix (MenACWY-TT). Summary of Product Characteristics, Sandwich, UK, Pfizer Limited, 2021."},{"issue":"14","key":"10.1016\/j.vaccine.2022.11.048_b0060","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1016\/j.vaccine.2018.02.013","article-title":"Immunogenicity and safety of one or two doses of the quadrivalent meningococcal vaccine MenACWY-TT given alone or with the 13-valent pneumococcal conjugate vaccine in toddlers: A phase III, open-label, randomised study","volume":"36","author":"Cutland","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.11.048_b0065","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1080\/21645515.2019.1593082","article-title":"A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines","volume":"15","author":"Findlow","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2022.11.048_b0070","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1080\/14760584.2021.1940144","article-title":"Correlates of protection for meningococcal surface protein vaccines: lessons from the past","volume":"21","author":"Findlow","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2022.11.048_b0075","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1084\/jem.129.6.1307","article-title":"Human immunity to the meningococcus. I. The role of humoral antibodies","volume":"129","author":"Goldschneider","year":"1969","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2022.11.048_b0080","unstructured":"European Centre for Disease Prevention and Control. Meningococcal disease: Recommended vaccinations, https:\/\/vaccine-schedule.ecdc.europa.eu\/Scheduler\/ByDisease?SelectedDiseaseId=48&SelectedCountryIdByDisease=-1; [accessed October 27, 2022]."},{"key":"10.1016\/j.vaccine.2022.11.048_b0085","unstructured":"Government of Canada. Meningococcal vaccine: Canadian Immunization Guide, https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/page-13-meningococcal-vaccine.html; 2020 [accessed November 3, 2021]."},{"key":"10.1016\/j.vaccine.2022.11.048_b0090","unstructured":"Australian Government Department of Health. National Immunisation Program Schedule 1 July 2020 For All Non-Indigenous People; 2020."},{"key":"10.1016\/j.vaccine.2022.11.048_b0095","doi-asserted-by":"crossref","first-page":"e298","DOI":"10.1097\/INF.0000000000000897","volume":"34","author":"Vesikari","year":"2015","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2022.11.048_b0100","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.4161\/hv.22166","article-title":"Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers","volume":"8","author":"Vesikari","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2022.11.048_b0105","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/21645515.2015.1058457","article-title":"Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine","volume":"12","author":"Vesikari","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2022.11.048_b0110","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1097\/INF.0000000000001123","article-title":"Five-year Antibody Persistence and Booster Response After 1 or 2 Doses of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Healthy Children","volume":"35","author":"Klein","year":"2016","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2022.11.048_b0115","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1016\/j.vaccine.2020.02.048","article-title":"Persistence of bactericidal antibodies following primary and booster MenACWY-TT vaccination of toddlers: A review of clinical studies","volume":"38","author":"Webber","year":"2020","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2022.11.048_b0120","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1080\/21645515.2020.1744363","article-title":"Efficacy and safety of a booster dose of the meningococcal A, C, W, Y-tetanus toxoid conjugate vaccine administered 10 years after primary vaccination and long-term persistence of tetanus toxoid conjugate or polysaccharide vaccine","volume":"16","author":"Quiambao","year":"2020","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2022.11.048_b0125","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1186\/s12879-020-05104-5","article-title":"A phase 2b\/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years","volume":"20","author":"Borja-Tabora","year":"2020","journal-title":"BMC Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2022.11.048_b0130","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1080\/21645515.2020.1746110","article-title":"Ten-Year Antibody Persistence and Booster Response to MenACWY-TT Vaccine After Primary Vaccination at 1\u201310 Years of Age","volume":"16","author":"Vesikari","year":"2020","journal-title":"Hum Vaccin Immunother"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2201461X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X2201461X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:23:01Z","timestamp":1759404181000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X2201461X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":26,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S0264410X2201461X"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.11.048","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase 3, randomized, controlled, open-label study to evaluate the persistence up to 5\u00a0years of 1 or 2 doses of meningococcal conjugate vaccine MenACWY-TT given with or without 13-valent pneumococcal conjugate vaccine in 12\u201314-month-old children","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.11.048","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Pfizer Inc. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}